Pieris confirms in vivo activity of potent VEGF-specific Anticalin
PRS-050 targets VEGF, a key positive regulator of angiogenesis important in several diseases including cancer and neovascular eye disorders. According to the company, PRS-050 binds to all splice variants of VEGF-A with picomolar affinity and antagonizes VEGF binding to its receptors VEGF-R1 and VEGF-R2. PRS-050 shall inhibit in vitro VEGFinduced human endothelial cell proliferation with favorable potency compared to all currently approved VEGF antagonists. Complete inhibition of angiogenic and vascular permeability activities of VEGF by the Anticalin have now been demonstrated in appropriate in vivo models, according to Pieris.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.